You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Fourth Quarter U.S. Tarceva Sales Increased 17% on Prior Year to $137 Million Total Global Tarceva Sales for 2009 Top $1.2 Billion MELVILLE, N.Y., Jan 12, 2010 (BUSINESS WIRE) -- OSI...
MELVILLE, N.Y., Dec 29, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065,...
GAITHERSBURG, Md., Dec 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG)(OTCQX: RHHBY), announced...
MOTTEP Honors Astellas for Commitment to Transplant Community Deerfield, IL (December 7, 2009) – Astellas Pharma US, Inc. was inducted into the National Minority Organ Tissue Transplant...
Read more about Astellas Inducted into National Minority Transplant Hall of Fame
MELVILLE, N.Y., Nov 16, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) will review the use of Tarceva(R)...
Follow U.S. news
